Fung Simon
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2025 May 19. doi: 10.1007/s40265-025-02193-x.
Vonoprazan (Voquezna) is a potassium-competitive acid blocker (PCAB) with improved pharmacodynamic and pharmacokinetic properties compared with proton-pump inhibitors (PPIs) that allow for stronger control of gastric acid with once-daily oral administration and no requirement to be taken in relation to timing of meals for optimal efficacy. In the USA, vonoprazan has been approved as a first-in-class treatment for healing and maintenance of healing of erosive esophagitis, and for relief of heartburn in adult patients with erosive esophagitis and non-erosive gastro-esophageal reflux disease (GERD). In pivotal phase III trials, vonoprazan was non-inferior to the PPI lansoprazole in healing and superior to lansoprazole in maintenance of healing of erosive esophagitis, and was superior to placebo for treating heartburn in US patients with non-erosive GERD. Vonoprazan was generally well tolerated; the most common adverse events included abdominal pain, constipation, diarrhea, nausea, and dyspepsia. Vonoprazan is, therefore, a valuable addition to the therapies available for adults with erosive esophagitis and non-erosive GERD.
沃克索纳（Vonoprazan）是一种钾离子竞争性酸阻滞剂（PCAB），与质子泵抑制剂（PPI）相比，其药效学和药代动力学特性有所改善，每日口服一次即可更强地控制胃酸，且无需根据进餐时间服用以达到最佳疗效。在美国，沃克索纳已被批准作为治疗糜烂性食管炎愈合及维持愈合的同类首创药物，以及用于缓解糜烂性食管炎成年患者和非糜烂性胃食管反流病（GERD）患者的烧心症状。在关键的III期试验中，沃克索纳在糜烂性食管炎愈合方面不劣于PPI兰索拉唑，在维持愈合方面优于兰索拉唑，并且在治疗美国非糜烂性GERD患者的烧心症状方面优于安慰剂。沃克索纳总体耐受性良好；最常见的不良事件包括腹痛、便秘、腹泻、恶心和消化不良。因此，沃克索纳是糜烂性食管炎和非糜烂性GERD成年患者现有治疗方法的一个有价值补充。
